Chemistry: molecular biology and microbiology – Process of utilizing an enzyme or micro-organism to destroy... – Resolution of optical isomers or purification of organic...
Patent
1995-06-07
1998-03-17
Saucer, Sandra E.
Chemistry: molecular biology and microbiology
Process of utilizing an enzyme or micro-organism to destroy...
Resolution of optical isomers or purification of organic...
435118, C12P 4100
Patent
active
057285756
ABSTRACT:
A process for the resolution of a racemic mixture of nucleoside enantiomers that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers. The nucleoside enantiomer (-)-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane is an effective antiviral agent against HIV, HBV, and other viruses replicating in a similar manner.
REFERENCES:
patent: 3116268 (1963-12-01), Farago
patent: 3116282 (1963-12-01), Hunter
patent: 3553192 (1971-01-01), Gauri
patent: 4000137 (1976-12-01), Dvonch et al.
patent: 4336381 (1982-06-01), Nagata et al.
patent: 4861759 (1989-08-01), Hiroaki et al.
patent: 4879277 (1989-11-01), Mitsuya et al.
patent: 4900828 (1990-02-01), Belica et al.
patent: 4916122 (1990-04-01), Chu et al.
patent: 4963533 (1990-10-01), de Clercq et al.
patent: 4968674 (1990-11-01), Taniyama et al.
patent: 5011774 (1991-04-01), Farina et al.
patent: 5041449 (1991-08-01), Belleau et al.
patent: 5047407 (1991-09-01), Belleau et al.
patent: 5059690 (1991-10-01), Zahler et al.
patent: 5071983 (1991-12-01), Koszalka et al.
patent: 5089500 (1992-02-01), Daluge
patent: 5151426 (1992-09-01), Belleau et al.
patent: 5179104 (1993-01-01), Chu et al.
patent: 5185437 (1993-02-01), Koszalka et al.
patent: 5204466 (1993-04-01), Liotta et al.
patent: 5210085 (1993-05-01), Liotta et al.
patent: 5215971 (1993-06-01), Datema et al.
patent: 5234913 (1993-08-01), Furman, Jr. et al.
patent: 5246924 (1993-09-01), Fox et al.
patent: 5248776 (1993-09-01), Chu et al.
patent: 5270315 (1993-12-01), Belleau et al.
patent: 5276151 (1994-01-01), Liotta
patent: 5409906 (1995-04-01), Datema et al.
patent: 5432165 (1995-07-01), Adair et al.
patent: 5444063 (1995-08-01), Schinazi
patent: 5446029 (1995-08-01), Eriksson et al.
patent: 5466806 (1995-11-01), Belleau et al.
patent: 5486520 (1996-01-01), Belleau et al.
patent: 5521161 (1996-05-01), Malley et al.
patent: 5532246 (1996-07-01), Belleau et al.
patent: 5539116 (1996-07-01), Liotta et al.
patent: 5587480 (1996-12-01), Belleau et al.
Abobo, et al, "Pharmacokinetics of 2',3'-Dideoxy-5-fluoro-3 '-thiacytidine in Rats," J. of Pharmaceutical Sciences, 83(1):96-99 (1994).
Agrofoglio, et al., "Synthesis of Carbocyclic Nucleosides," Tetrahedron 50(36):10611-10670 (1994).
Asseline, et al., "Synthesis and physicochemical properties of oligonucleotides built with either .beta.-L or .alpha.-L nucleotides units and covalently linked to an acridine derivative," Nucl. Acids Res., 19(15):4067-4074 (1991).
Balzarini, J., et al., "Potent and Selective Anti-HTLV-III/LAV Activity of 2',3'-Dideoxycytidinene, the 2',3'-Unsaturated Derivative of 2',3'-Dideoxycytidine," Biochemical and Biophysical Research Communications, 140(2):735-742 (1986).
Balzarini, et al., "2'-3'-Didehydro-2'-3'-Dideoxy-5-Chlorocytidine is a Selective Anti-Retrovirus Agent," Biochem. and Biophys. Res. Comm., 164(3):1190-1197 (1989).
Balzarini, J., et al., "5-Chloro-Substituted Derivatives of 2'-3'-Didehydro-2'-3'-Dideoxyuridine, 3'-Fluoro-2'3'-Dideoxyuridine and 3'-Azido-2'-3'-Dideoxyuridine as Anti-HIV Agents," Biochemical Pharmacol., 38(6):8669-874 (1989).
Beach, J.W., et al., "Synthesis of Enantiomerically Pure (2'R, 5'S)-(1)-1 Against Hepatitis B Virus (HBV) and Human Immunodeficiency Virus (HIV)," J. Org. Chem., 57:2217-2219 (1992).
Belleau, B., et al., "Design and Activity of a Novel Class of Nucleoside Analogs Effective Against HIV-1," International Conference on AIDS, Montreal, Quebec, Canada, June 4-9, 1989.
Biron, et al., "Anti-HIV Activity of the combination of Didanosine and Hydroxyurea in HIV-1-Infected Individuals," J. of Acquired Immune Deficiency Syndromes and Human Retrovirology, 10:36-40 (1995).
Borthwick, et al., "Synthesis and Enzymatic Resolution of Carbocyclic 2'-Ara-Fluoro-Guanosine: A Potent New Anti-Herpetic Agent," J. Chem. Soc. Commun., vol. 10. pp. 656-658 (1988).
Bouffard, D.Y., et al., "Kinetic Studies on 2'2'-Difluorodeoxycytidine(Gemcitabine) with Purified Human Deoxycytidine Kinase and Cytidine Deaminase," Biochem. Pharmacol., 45(9):1857-1861 (1993).
Carter, et al., "Activities of (-)-Carbovir and 3'-Azido-3'-Deoxythymidine Against Human Immunodeficiency Virus In Vitro," Antimicrobial Agents and Chemotherapy, 34(6): 1297-1300 (1990).
Chang, C-N., et al., "Biochemical Pharmacology of (+) and (-)-2',3'-Dideoxy-3'-Thiacytidine as Anti-Hepatitis B Virus Agents", J. Biol. Chem., 267(31):22414-22420 (1992).
Chang, Chien-Neng, et al., "Deoxycytidine Deaminase-resistant Steroisomer Is the Active Form of(.+-.)-2',3'-Dideoxy-3'-thiacytidine in the Inhibition of Hepatitis B Virus Replication," The Journal of Biological Chemistry, 267(20):13938-13942 (1992).
Chang, Chungming, et al., "Production of Hepatitis B Virus In Vitro by Transient Expression of Cloned HBV DNA in a Hepatoma Cell Line," The EMBO Journal, 6(3):675-680 (1987).
Chen, Chin-Ho, et al., "Delayed Cytotoxicity and Selective Loss of Mitochondrial DNA in Cells Treated with the Anti-Human Immunodeficiency Virus Compound 2',3'-Dideoxycytidine," The Journal of Biological Chemistry, 264(20):11934-11937 (1989).
Choi, et al., "Synthesis, Anti-Human Immunodeficiency Virus, and Anti-Hepatitis B Virus Activity of Pyrimidine Oxathiolane Nucleosides," Bioorgan. and Med. Chem. Lett., 3(4):693-696 (1993).
Choi, et al., "In Situ Complexation Directs the Stereochemistry of N-Glycosylation in the Synthesis of Oxathiolanyl and Dioxolanyl Nucleoside Analogues," J. Am. Chem. Soc., 113:9377-9379 (1991).
Chottiner, E.G., "Cloning and Expression of Human Deocycytidine Kinase cDNA," Proc. Natl. Acad. Sci. USA, 88:1531-1535 (1991).
Chu, et al., "Use of 2'-Fluoro-5-Metyl-I.beta.-L-Arabinofuranosyluracil as a Novel Antiviral Agent for Hepatitis B Virus and Epstein-Barr Virus," Antimicrob. Agents. Chemother., 39(4):979-981 (1995).
Chu, C.K., et al., "An Efficient Total Synthesis of 3'-Azido-3'-Deoxythiymidine (AZT) and 3'-Azido-2',3'-Dideoxyuridine (AZDDU, CS-87) from D-Mannitol," Tetrahedron Lett., 29(42):5349-5352 (1988).
Chu, et al., "Comparative Activity of 2',3'-Saturated and Unsaturated Pyrimidine and Purine Nucleosides Against Human Immunodeficiency Virus Type 1 in Peripheral Blood Mononuclear Cells," Biochem. Pharm., 37(19):3543-3548 (1988).
Chu, et al., "Structure-Activity Relationships of Pyrimidine Nucleosides as Antiviral Agents for Human Immunodeficiency Virus Type 1 in Peripheral Blood Mononuclear Cells," J. Med. Chem., 32:612 (1989).
Coates, et al., "The Separated Enantiomers of 2'-Deoxy-3'-thiacytidine(BCH-189) both Inhibit Human Immunodeficiency Virus Replication in vitro," Antimicrob. Agents Chemother., 36(1):202-205 (1992).
Condreay, et al., "Evaluation of the Potent Anti-Hepatitis B Virus Agent Novel In Vivo Model," Antimicrobial Agents and Chemotherapy, 616-619 (1992).
Cretton, E., et al., "Catabolism of 3'-Azido-3'-Deoxythymidine in Heptaocytes and Liver Microsomes, with Evidence of Formation of 3'-Amino-3'Deoxythymidine, a Highly Toxic Catabolite for Human Bone Marrow Cells," Molecuilar Pharmacology, 39:258-266 (1991).
Cretton, E., et al., "Pharmokinetics of 3'-Azido-3'-Dexoythymidine and its Catabolites and Interactions with Probenecid in Rhesus Monkeys," Antimicrobial Agents and Chemotherapy, 35(5):801-807 (1991).
Davisson, et al., "Synthesis of Nucleotide 5'-Diphosphates from 5'-O-Tosyl Nucleosides," J. Org. Chem., 52:1794-1801 (1987).
Di Bisceglie, Adrian M., Rustgi, Vinod K. et al., "Hepatocellular Carcinoma," NIH Conference, Annals of Internal Medicine, 108:390-401 (1988).
Doong, Shin-Lian., et al., "Inhibition of the Replication of Hepatitis B Virus in vitro by 2',3'-Dideoxy-3'-Thiacytidine and Related Analogues," Natl. Acad Sci. USA, 88:8495-8499 (1991).
Feorino, et al., "Prevention of activation of HIV-1 by antiviral agents in OM-10.1 cells," Antiviral Chem. & Chemotherapy, 4(1):55-63 (1993).
Frick, et al, "Pharmacokinetics, Oral Bioavailability, and Metabolic Disposition in Rats of Nucleoside Analog Active against Human Immunodeficiency Virus and Hepatitis B Virus," Antimicrobial Agents and Chemotherapy, 37(11):2285-2292 (1993).
Frick, et al., "Pharm
Choi Woo-Baeg
Liotta Dennis C.
Emory University
Saucer Sandra E.
LandOfFree
Method of resolution of 1,3-oxathiolane nucleoside enantiomers does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of resolution of 1,3-oxathiolane nucleoside enantiomers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of resolution of 1,3-oxathiolane nucleoside enantiomers will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-956837